Pharmaceutical major Lupin will establish a research and development (R&D) unit in Aurangabad to make generic drug products to fulfill the growing demand in Latin America, Africa and Australia.

The company will employ around 50 to 60 people for its new research and development facility, which is likely to be completed by the next in three months.

Mr. Nilesh Gupta, group president and executive director said that the company presently has an R&D team of 700-plus scientists.

The new centre would permit the company to file product dossiers for marketing approvals in all emerging nations.

Moreover, the company, on June 04, announced that its US based arm Lupin Pharmaceuticals (LPI) has bagged the US food and drug administration (US FDA) nod for lamotrigine tabs.

The company received nod to make and sell lamotrigine tabs in the strengths of 25, 100, 150 and 200 mg.

Lamotrigine tabs are used to treat bipolar-I disorder.

Lamotrigine tabs are a generic edition of GlaxoSmithKline's branded drug Lamictal, the statement said.

The twelve monthly sales of Lamotrigine stood at around $452 million in the US market. (With Inputs from Agencies)